Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$0.07.

  • ImmunityBio's EPS (Basic) rose 4166.67% to -$0.07 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.39, marking a year-over-year increase of 5666.67%. This contributed to the annual value of -$0.59 for FY2024, which is 4841.75% up from last year.
  • As of Q3 2025, ImmunityBio's EPS (Basic) stood at -$0.07, which was up 4166.67% from -$0.1 recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's EPS (Basic) peaked at -$0.07 during Q3 2025, and registered a low of -$0.38 during Q4 2023.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.22 (2021), whereas its average is -$0.21.
  • In the last 5 years, ImmunityBio's EPS (Basic) crashed by 11027.51% in 2021 and then surged by 7766.65% in 2024.
  • ImmunityBio's EPS (Basic) (Quarter) stood at -$0.23 in 2021, then fell by 17.39% to -$0.27 in 2022, then plummeted by 40.74% to -$0.38 in 2023, then skyrocketed by 77.67% to -$0.08 in 2024, then rose by 17.52% to -$0.07 in 2025.
  • Its last three reported values are -$0.07 in Q3 2025, -$0.1 for Q2 2025, and -$0.15 during Q1 2025.